BR0112272A - Anticorpo monoclonal anti-trkc agonista, cadeia pesada de anticorpo anti-trkc, cadeia leve de anticorpo anti-trkc, cadeia pesada de anticorpo anti-trkc murino, cadeia pesada de anticorpo anti-trkc humano, anticorpo agonista anti-trkc murino, anticorpo agonista anti-trkc humano, moléculas de ácido nucléico isolado, moléculas de ácido nucléico, vetor, linhagens de células hospedeiras, linhagens de células de hibridoma, célula hospedeira, polipeptìdeo, composição farmacêutica, método para o tratamento de neuropatia ou doença neurodegenerativa ou reparo de uma célula nervosa lesionada, método para aumentar a proliferação, manutenção ou regeneração de neurÈnios periféricos, método para o tratamento de doença ou condição que envolve a degeneração celular em um paciente mamìfero, método de indução de angiogênese, método de fabricação de um anticorpo anti-trkc, usos de um anticorpo - Google Patents
Anticorpo monoclonal anti-trkc agonista, cadeia pesada de anticorpo anti-trkc, cadeia leve de anticorpo anti-trkc, cadeia pesada de anticorpo anti-trkc murino, cadeia pesada de anticorpo anti-trkc humano, anticorpo agonista anti-trkc murino, anticorpo agonista anti-trkc humano, moléculas de ácido nucléico isolado, moléculas de ácido nucléico, vetor, linhagens de células hospedeiras, linhagens de células de hibridoma, célula hospedeira, polipeptìdeo, composição farmacêutica, método para o tratamento de neuropatia ou doença neurodegenerativa ou reparo de uma célula nervosa lesionada, método para aumentar a proliferação, manutenção ou regeneração de neurÈnios periféricos, método para o tratamento de doença ou condição que envolve a degeneração celular em um paciente mamìfero, método de indução de angiogênese, método de fabricação de um anticorpo anti-trkc, usos de um anticorpoInfo
- Publication number
- BR0112272A BR0112272A BR0112272-0A BR0112272A BR0112272A BR 0112272 A BR0112272 A BR 0112272A BR 0112272 A BR0112272 A BR 0112272A BR 0112272 A BR0112272 A BR 0112272A
- Authority
- BR
- Brazil
- Prior art keywords
- trkc
- antibody
- heavy chain
- agonist
- nucleic acid
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 7
- 210000004027 cell Anatomy 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 7
- 102000039446 nucleic acids Human genes 0.000 title abstract 4
- 108020004707 nucleic acids Proteins 0.000 title abstract 4
- 150000007523 nucleic acids Chemical class 0.000 title abstract 4
- 230000007850 degeneration Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 208000033808 peripheral neuropathy Diseases 0.000 title abstract 3
- 210000004408 hybridoma Anatomy 0.000 title abstract 2
- 238000012423 maintenance Methods 0.000 title abstract 2
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 210000002569 neuron Anatomy 0.000 title abstract 2
- 230000007823 neuropathy Effects 0.000 title abstract 2
- 201000001119 neuropathy Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 230000035755 proliferation Effects 0.000 title abstract 2
- 230000008929 regeneration Effects 0.000 title abstract 2
- 238000011069 regeneration method Methods 0.000 title abstract 2
- 230000008439 repair process Effects 0.000 title abstract 2
- 241001529936 Murinae Species 0.000 title 2
- 230000033115 angiogenesis Effects 0.000 title 1
- 230000006698 induction Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 210000002856 peripheral neuron Anatomy 0.000 title 1
- 230000005779 cell damage Effects 0.000 abstract 2
- 208000037887 cell injury Diseases 0.000 abstract 2
- 101150117329 NTRK3 gene Proteins 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 229940028313 malotic Drugs 0.000 abstract 1
- 230000003278 mimic effect Effects 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000047459 trkC Receptor Human genes 0.000 abstract 1
- 108010064892 trkC Receptor Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Abstract
"ANTICORPO MONOCLONAL ANTI-trkC AGONISTA, CADEIA PESADA DE ANTICORPO ANTI-trkC, CADEIA LEVE DE ANTICORPO ANTI-trkC, CADEIA PESADA DE ANTICORPO ANTI-trkC MURINO, CADEIA PESADA DE ANTICORPO ANTI-trkC HUMANO, ANTICORPO AGONISTA ANTI-trkC MURINO, ANTICORPO AGONISTA ANTI-trkC HUMANO, MOLéCULAS DE áCIDO NUCLéICO ISOLADO, MOLéCULAS DE áCIDO NUCLéICO, VETOR, LINHAGENS DE CéLULAS HOSPEDEIRAS, LINHAGENS DE CéLULAS DE HIBRIDOMA, CéLULA HOSPEDEIRA, POLIPEPTìDEO, COMPOSIçãO FARMACêUTICA, MéTODO PARA O TRATAMENTO DE NEUROPATIA OU DOENçA NEURODEGENERATIVA OU REPARO DE UMA CéLULA NERVOSA LESIONADA, MéTODO PARA AUMENTAR A PROLIFERAçãO, MANUTENçãO OU REGENERAçãO DE NEURÈNIOS PERIFéRICOS, MéTODO PARA O TRATAMENTO DE DOENçA OU CONDIçãO QUE ENVOLVE A DEGENERAçãO CELULAR EM UM PACIENTE MAMìFERO, MéTODO DE INDUçãO DE ANGIOGêNESE, MéTODO DE FABRICAçãO DE UM ANTICORPO ANTI-trkC AGONISTA, USOS DE UM ANTICORPO" A presente invenção refere-se a anticorpos monocionais anti-trkc agonistas que mimetizam certas atividades biológicas de NT-3, ligante nativo de trkc. A presente invenção refere-se ainda à utilização desses anticorpos na prevenção e/ou tratamento de degeneração celular, incluindo danos às células nervosas associados a lesões agudas do sistema celular nervoso e doenças neurodegenerativas crónicas, incluindo neuropatia periférica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21314100P | 2000-06-22 | 2000-06-22 | |
| US23831900P | 2000-10-05 | 2000-10-05 | |
| PCT/US2001/020153 WO2001098361A2 (en) | 2000-06-22 | 2001-06-22 | Agonist anti-trk-c monoclonal antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0112272A true BR0112272A (pt) | 2003-05-06 |
Family
ID=26907807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0112272-0A BR0112272A (pt) | 2000-06-22 | 2001-06-22 | Anticorpo monoclonal anti-trkc agonista, cadeia pesada de anticorpo anti-trkc, cadeia leve de anticorpo anti-trkc, cadeia pesada de anticorpo anti-trkc murino, cadeia pesada de anticorpo anti-trkc humano, anticorpo agonista anti-trkc murino, anticorpo agonista anti-trkc humano, moléculas de ácido nucléico isolado, moléculas de ácido nucléico, vetor, linhagens de células hospedeiras, linhagens de células de hibridoma, célula hospedeira, polipeptìdeo, composição farmacêutica, método para o tratamento de neuropatia ou doença neurodegenerativa ou reparo de uma célula nervosa lesionada, método para aumentar a proliferação, manutenção ou regeneração de neurÈnios periféricos, método para o tratamento de doença ou condição que envolve a degeneração celular em um paciente mamìfero, método de indução de angiogênese, método de fabricação de um anticorpo anti-trkc, usos de um anticorpo |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US7384632B2 (pt) |
| EP (1) | EP1292680B1 (pt) |
| JP (1) | JP2004500873A (pt) |
| KR (1) | KR100823764B1 (pt) |
| CN (1) | CN100519749C (pt) |
| AT (1) | ATE446366T1 (pt) |
| AU (2) | AU2001271422B2 (pt) |
| BR (1) | BR0112272A (pt) |
| CA (1) | CA2412494C (pt) |
| DE (1) | DE60140252D1 (pt) |
| DK (1) | DK1292680T3 (pt) |
| HU (1) | HU228310B1 (pt) |
| IL (2) | IL153375A0 (pt) |
| MX (1) | MXPA02012602A (pt) |
| NZ (1) | NZ523105A (pt) |
| PL (1) | PL208113B1 (pt) |
| WO (1) | WO2001098361A2 (pt) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5877016A (en) * | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
| DK1290028T3 (da) | 2000-06-05 | 2010-04-26 | Brigham & Womens Hospital | Gen, der koder for en multidrug-resistens-human P-glycoprotein-homolog på kromosom 7p15-21, og anvendelser deraf |
| ATE446366T1 (de) * | 2000-06-22 | 2009-11-15 | Genentech Inc | Agonistische monoklonale antikörper gegen trkc |
| GB0210783D0 (en) * | 2002-05-10 | 2002-06-19 | Polonelli Luciano | Anti-microbial polypeptides |
| EP1561107A1 (en) * | 2002-11-13 | 2005-08-10 | Micromet AG | Method for identifying antigen specific b cells |
| JP2006513187A (ja) * | 2002-12-23 | 2006-04-20 | ライナット ニューロサイエンス コーポレイション | タキソール誘発性感覚性ニューロパシーを処置するための方法 |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US20070014786A1 (en) * | 2003-03-20 | 2007-01-18 | Rinat Neuroscience Corp. | Methods for treating taxol-induced gut disorder |
| US7968690B2 (en) | 2003-12-23 | 2011-06-28 | Rinat Neuroscience Corp. | Agonist anti-trkC antibodies and methods using same |
| AR054260A1 (es) * | 2005-04-26 | 2007-06-13 | Rinat Neuroscience Corp | Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos |
| MX2007015292A (es) * | 2005-06-06 | 2008-02-21 | Wyeth Corp | Anticuerpos monoclonales anti-trkb y sus usos. |
| US7700739B2 (en) * | 2005-06-30 | 2010-04-20 | Abbott Laboratories | IL-12/p40 binding proteins |
| AU2006319358B2 (en) | 2005-11-30 | 2012-01-19 | AbbVie Deutschland GmbH & Co. KG | Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
| KR101439828B1 (ko) | 2005-11-30 | 2014-09-17 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| NL2000464C2 (nl) | 2006-02-02 | 2007-09-11 | Rinat Neuroscience Corp | Werkwijzen voor het behandelen van ongewenst gewichtsverlies of eetstoornissen door het toedienen van een TRKB-agonist. |
| SI2772535T1 (sl) | 2006-05-31 | 2022-08-31 | Children's Medical Center Corporation | ABC5 pozitivne mezenhimske matične celice kot imunomodulatorji |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| JP5576659B2 (ja) * | 2006-12-05 | 2014-08-20 | ザ ロイヤル インスティテューション フォー ジ アドバンスメント オブ ラーニング／ マギル ユニバーシティ | Ｔｒｋレセプター調節因子の使用方法 |
| IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| WO2008127656A1 (en) | 2007-04-12 | 2008-10-23 | The Brigham And Women's Hospital, Inc. | Targeting abcb5 for cancer therapy |
| EP2262837A4 (en) * | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| CA2724830A1 (en) * | 2008-05-21 | 2009-11-26 | Centre Leon Berard | Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma |
| PT2350075E (pt) | 2008-09-22 | 2014-06-09 | Array Biopharma Inc | Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase |
| SG10201914059WA (en) | 2008-10-22 | 2020-03-30 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
| US11542328B2 (en) | 2008-11-14 | 2023-01-03 | The Brigham And Women's Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
| EP2356446A4 (en) | 2008-11-14 | 2014-03-19 | Brigham & Womens Hospital | DIAGNOSTIC AND THERAPEUTIC METHODS RELATING TO CANCER STEM CELLS |
| SI2949666T1 (sl) | 2008-12-19 | 2019-03-29 | Biogen International Neuroscience Gmbh | Človeška anti alfa-sinukleinska protitelesa |
| US20100272640A1 (en) | 2009-04-24 | 2010-10-28 | Ozge Alper | Monoclonal Antibodies Against PCBP-1 Antigens, and Uses Therefor |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| LT3023438T (lt) | 2009-09-03 | 2020-05-11 | Merck Sharp & Dohme Corp. | Anti-gitr antikūnai |
| CA2796339C (en) | 2010-04-15 | 2020-03-31 | Abbott Laboratories | Amyloid-beta binding proteins |
| MX365251B (es) | 2010-05-20 | 2019-05-28 | Array Biopharma Inc | Compuestos macrocíclicos como inhibidores de trk cinasa. |
| EP2596365A4 (en) * | 2010-07-14 | 2013-12-18 | Alper Biotech Llc | MONOCLONAL ANTIBODIES TO PCBP1 ANTIGENES AND APPLICATIONS THEREOF |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| WO2012027821A1 (en) * | 2010-09-03 | 2012-03-08 | The Royal Institution For The Advancement Of Learning / Mcgill University | A trkc receptor agonist antibody to treat neurodegenerative and motor neuron diseases |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| AU2011336470B8 (en) | 2010-12-01 | 2017-09-14 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| EP4086338A1 (en) * | 2011-03-17 | 2022-11-09 | Minerva Biotechnologies Corporation | Method for making pluripotent stem cells |
| CA2839563C (en) | 2011-06-23 | 2019-10-29 | Biogen Idec International Neuroscience Gmbh | Anti-alpha synuclein binding molecules |
| WO2013006449A2 (en) * | 2011-07-01 | 2013-01-10 | The Trustees Of The University Of Pennsylvania | Anti-properdin antibodies and uses thereof |
| CN104303186B (zh) * | 2012-05-09 | 2018-12-11 | 皇家飞利浦有限公司 | 介入信息代理医学追踪接口 |
| CN104870474B (zh) | 2012-10-04 | 2019-03-12 | 诺沃姆德治疗公司 | 用于治疗溶血性疾病的旁路途径特异性抗体 |
| CN113354649A (zh) | 2014-11-16 | 2021-09-07 | 阵列生物制药公司 | 一种新的晶型 |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| MA44936A1 (fr) | 2015-06-01 | 2021-09-30 | Loxo Oncology Inc | Méthodes de diagnostic et de traitement du cancer |
| PE20180041A1 (es) | 2015-06-05 | 2018-01-09 | Novartis Ag | Anticuerpos dirigidos a la proteina morfogenetica osea (bmp9) y metodos a partir de estos |
| PL3322706T3 (pl) | 2015-07-16 | 2021-07-19 | Array Biopharma, Inc. | Podstawione związki pirazolo[1,5-a]pirydynowe jako inhibitory kinazy ret |
| CA2993645A1 (en) | 2015-07-28 | 2017-02-02 | Otonomy, Inc. | Trkb or trkc agonist compositions and methods for the treatment of otic conditions |
| CA3003153A1 (en) | 2015-10-26 | 2017-05-04 | Loxo Oncology, Inc. | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| BR112018008904A2 (pt) | 2015-11-03 | 2018-11-27 | Janssen Biotech Inc | anticorpos que se ligam especificamente a tim-3 e seus usos |
| US20170233480A1 (en) | 2015-12-31 | 2017-08-17 | Development Center For Biotechnology | Anti-vegfr antibody and uses thereof |
| PE20181888A1 (es) | 2016-04-04 | 2018-12-11 | Loxo Oncology Inc | Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| KR20210010652A (ko) | 2016-04-04 | 2021-01-27 | 록쏘 온콜로지, 인코포레이티드 | 소아암을 치료하는 방법 |
| RU2745953C2 (ru) | 2016-05-18 | 2021-04-05 | Локсо Онколоджи, Инк. | Способ получения (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)-пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида и его солей |
| WO2018005830A1 (en) | 2016-06-29 | 2018-01-04 | Otonomy, Inc. | Triglyceride otic formulations and uses thereof |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JP7128529B2 (ja) * | 2016-12-23 | 2022-08-31 | アールイーエムディー バイオセラピューティクス，インコーポレイテッド | プログラム死リガンド－１（ｐｄ－ｌ１）に結合する抗体を使用する免疫 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
| EP4095161A1 (en) * | 2017-03-15 | 2022-11-30 | Tsinghua University | Novel anti-trkb antibodies |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| EP3648757A4 (en) * | 2017-07-03 | 2020-11-25 | Development Center for Biotechnology | ANTI-VEGFR ANTIBODIES AND USES THEREOF |
| JP7263320B2 (ja) | 2017-08-22 | 2023-04-24 | バイオジェン・エムエイ・インコーポレイテッド | 抗ベータアミロイド抗体を含有する医薬組成物 |
| US11786551B2 (en) | 2017-09-26 | 2023-10-17 | The Trustees Of The University Of Pennsylvania | Methods for treating heart disease via redirected T cell immunotherapies |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| AU2018346978B2 (en) * | 2017-10-13 | 2024-02-15 | Mapp Biopharmaceutical, Inc. | Anti-respiratory syncytial virus antibodies, methods of their generation and use |
| US20190247398A1 (en) | 2017-10-26 | 2019-08-15 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
| US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
| TW201932464A (zh) | 2018-01-18 | 2019-08-16 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物 |
| TWI802635B (zh) | 2018-01-18 | 2023-05-21 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物 |
| US20210023086A1 (en) | 2018-03-29 | 2021-01-28 | Loxo Oncology, Inc. | Treatment of trk-associated cancers |
| KR102653681B1 (ko) | 2018-07-31 | 2024-04-03 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제 |
| ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
| EP3898615A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| CN113490666A (zh) | 2018-12-19 | 2021-10-08 | 奥瑞生物药品公司 | 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物 |
| BR112022005423A2 (pt) * | 2019-09-23 | 2022-06-21 | Univ Pennsylvania | Interrupção de tecidos tumorais por alvejamento de proteína de ativação de fibroblasto (fap) |
| CN117447602B (zh) * | 2023-12-22 | 2024-03-19 | 北京索莱宝科技有限公司 | 猪IgM的抗体及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2040099A1 (en) | 1990-05-01 | 1991-11-02 | Mariano Barbacid | Tyrosine kinase negative trkb |
| US5364769A (en) | 1990-09-25 | 1994-11-15 | Genentech, Inc. | Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production |
| US5348856A (en) * | 1991-07-08 | 1994-09-20 | E. R. Squibb & Sons, Inc. | DNA encoding TRKC protein |
| DE69330809T2 (de) | 1992-06-08 | 2002-05-16 | Takeda Chemical Industries Ltd | Therapeutisches Agens für Neutropenie |
| US5855885A (en) * | 1993-01-22 | 1999-01-05 | Smith; Rodger | Isolation and production of catalytic antibodies using phage technology |
| US5659791A (en) * | 1993-04-26 | 1997-08-19 | Microsoft Corporation | Encapsulation of extracted portions of documents into objects |
| AU697142B2 (en) | 1993-11-23 | 1998-10-01 | Genentech Inc. | Protein tyrosine kinases named Rse |
| ATE163231T1 (de) | 1993-11-23 | 1998-02-15 | Genentech Inc | Kinaserezeptoraktivierungstest |
| US5753225A (en) | 1993-12-03 | 1998-05-19 | The Regents Of The University Of California | Antibodies that mimic actions of neurotrophins |
| US5877016A (en) * | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
| JPH07285912A (ja) * | 1994-04-19 | 1995-10-31 | Asahi Chem Ind Co Ltd | 新規化合物ａｍ５２２１ |
| AU5752696A (en) * | 1995-05-18 | 1996-11-29 | Regents Of The University Of Michigan, The | Dna binding antibodies |
| JP3946256B2 (ja) * | 1995-09-11 | 2007-07-18 | 協和醗酵工業株式会社 | ヒトインターロイキン５受容体α鎖に対する抗体 |
| GB9525180D0 (en) | 1995-12-08 | 1996-02-07 | Univ Mcgill | Design of hormone-like antibodies with agonistic and antagonistic fuctions |
| JP2001527402A (ja) * | 1997-04-25 | 2001-12-25 | ジェネンテック，インコーポレーテッド | Ｎｇｆ変異体 |
| WO2000024415A2 (en) | 1998-10-28 | 2000-05-04 | Cornell Research Foundation, Inc. | Methods for regulating angiogenesis and vascular integrity using trk receptor ligands |
| US6656474B1 (en) * | 1999-01-15 | 2003-12-02 | Regeneron Pharmaceuticals, Inc. | Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders |
| ATE446366T1 (de) * | 2000-06-22 | 2009-11-15 | Genentech Inc | Agonistische monoklonale antikörper gegen trkc |
-
2001
- 2001-06-22 AT AT01950429T patent/ATE446366T1/de not_active IP Right Cessation
- 2001-06-22 PL PL359926A patent/PL208113B1/pl unknown
- 2001-06-22 IL IL15337501A patent/IL153375A0/xx unknown
- 2001-06-22 BR BR0112272-0A patent/BR0112272A/pt not_active IP Right Cessation
- 2001-06-22 DE DE60140252T patent/DE60140252D1/de not_active Expired - Lifetime
- 2001-06-22 NZ NZ523105A patent/NZ523105A/en not_active IP Right Cessation
- 2001-06-22 AU AU2001271422A patent/AU2001271422B2/en not_active Ceased
- 2001-06-22 US US10/312,316 patent/US7384632B2/en not_active Expired - Lifetime
- 2001-06-22 JP JP2002504316A patent/JP2004500873A/ja active Pending
- 2001-06-22 EP EP01950429A patent/EP1292680B1/en not_active Expired - Lifetime
- 2001-06-22 CA CA2412494A patent/CA2412494C/en not_active Expired - Lifetime
- 2001-06-22 MX MXPA02012602A patent/MXPA02012602A/es active IP Right Grant
- 2001-06-22 AU AU7142201A patent/AU7142201A/xx active Pending
- 2001-06-22 DK DK01950429.9T patent/DK1292680T3/da active
- 2001-06-22 KR KR1020027017506A patent/KR100823764B1/ko active IP Right Grant
- 2001-06-22 HU HU0300841A patent/HU228310B1/hu unknown
- 2001-06-22 CN CNB018144217A patent/CN100519749C/zh not_active Expired - Lifetime
- 2001-06-22 WO PCT/US2001/020153 patent/WO2001098361A2/en active IP Right Grant
-
2002
- 2002-12-11 IL IL153375A patent/IL153375A/en active IP Right Grant
-
2006
- 2006-10-16 US US11/581,865 patent/US7615383B2/en not_active Expired - Lifetime
-
2009
- 2009-06-04 US US12/478,501 patent/US20100003261A1/en not_active Abandoned
-
2011
- 2011-08-05 US US13/198,979 patent/US20120045443A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7384632B2 (en) | 2008-06-10 |
| HUP0300841A3 (en) | 2005-11-28 |
| NZ523105A (en) | 2004-07-30 |
| EP1292680B1 (en) | 2009-10-21 |
| US20040137513A1 (en) | 2004-07-15 |
| AU7142201A (en) | 2002-01-02 |
| PL359926A1 (en) | 2004-09-06 |
| US20100003261A1 (en) | 2010-01-07 |
| KR20030036240A (ko) | 2003-05-09 |
| DE60140252D1 (de) | 2009-12-03 |
| JP2004500873A (ja) | 2004-01-15 |
| WO2001098361A3 (en) | 2002-05-02 |
| HU228310B1 (en) | 2013-03-28 |
| US20120045443A1 (en) | 2012-02-23 |
| CA2412494A1 (en) | 2001-12-27 |
| US7615383B2 (en) | 2009-11-10 |
| IL153375A (en) | 2009-06-15 |
| HUP0300841A2 (hu) | 2004-06-28 |
| ATE446366T1 (de) | 2009-11-15 |
| CN1447857A (zh) | 2003-10-08 |
| US20070036794A1 (en) | 2007-02-15 |
| IL153375A0 (en) | 2003-07-06 |
| AU2001271422B2 (en) | 2005-12-22 |
| CA2412494C (en) | 2012-10-23 |
| EP1292680A2 (en) | 2003-03-19 |
| WO2001098361A9 (en) | 2003-03-06 |
| WO2001098361A2 (en) | 2001-12-27 |
| DK1292680T3 (da) | 2010-03-08 |
| MXPA02012602A (es) | 2003-05-14 |
| PL208113B1 (pl) | 2011-03-31 |
| KR100823764B1 (ko) | 2008-04-21 |
| CN100519749C (zh) | 2009-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0112272A (pt) | Anticorpo monoclonal anti-trkc agonista, cadeia pesada de anticorpo anti-trkc, cadeia leve de anticorpo anti-trkc, cadeia pesada de anticorpo anti-trkc murino, cadeia pesada de anticorpo anti-trkc humano, anticorpo agonista anti-trkc murino, anticorpo agonista anti-trkc humano, moléculas de ácido nucléico isolado, moléculas de ácido nucléico, vetor, linhagens de células hospedeiras, linhagens de células de hibridoma, célula hospedeira, polipeptìdeo, composição farmacêutica, método para o tratamento de neuropatia ou doença neurodegenerativa ou reparo de uma célula nervosa lesionada, método para aumentar a proliferação, manutenção ou regeneração de neurÈnios periféricos, método para o tratamento de doença ou condição que envolve a degeneração celular em um paciente mamìfero, método de indução de angiogênese, método de fabricação de um anticorpo anti-trkc, usos de um anticorpo | |
| Xu et al. | Recombinant DNA vaccine encoding multiple domains related to inhibition of neurite outgrowth: a potential strategy for axonal regeneration | |
| Brockes et al. | Purification and preliminary characterization of a glial growth factor from the bovine pituitary. | |
| Grumet et al. | Interactions with tenascin and differential effects on cell adhesion of neurocan and phosphacan, two major chondroitin sulfate proteoglycans of nervous tissue. | |
| Fawcett | Repair of spinal cord injuries: where are we, where are we going? | |
| Maina et al. | Hepatocyte growth factor, a versatile signal for developing neurons | |
| Gänzler-Odenthal et al. | Blocking N-cadherin function disrupts the epithelial structure of differentiating neural tissue in the embryonic chicken brain | |
| Glaser et al. | Neutralization of the chemokine CXCL10 reduces apoptosis and increases axon sprouting after spinal cord injury | |
| Reinehr et al. | Early remodelling of the extracellular matrix proteins tenascin‐C and phosphacan in retina and optic nerve of an experimental autoimmune glaucoma model | |
| Xiong et al. | Mitochondrial respiratory inhibition and oxidative stress elevate β-secretase (BACE1) proteins and activity in vivo in the rat retina | |
| Fowke et al. | Hyaluronan synthesis by developing cortical neurons in vitro | |
| BRPI0515604A (pt) | método para o tratamento de células de cáncer e método de tratamento de uma doença imune relacionada | |
| ATE511857T1 (de) | Anti-april monoklonaler antikörper und deren verwendung zur behandlung von immunerkrankungen oder krebs | |
| BRPI0412567A (pt) | anticorpo humano isolado, método de tratamento de uma condição causada pela expressão aumentada de ngf ou pela sensibilidade aumentada ao ngf em um paciente, composição farmacêutica, método para detectar ngf em uma amostra biológica, molécula de ácido nucleico, célula hospedeira, linhagem celular isolada, agente de ligação especìfica em ngf, anticorpo humano isolado ou fragmento de imunoglobulina imunologicamente funcional ou um ligante de antìgeno do mesmo, polinucleotìdeo, vetor de expressão, medicamento para tratar um distúrbio doloroso ou uma condição associada com a expressão aumentada de ngf ou a sensibilidade aumentada ao ngf, e, uso de uma quantidade farmaceuticamente efetiva de anticorpo | |
| BRPI0509367A (pt) | anticorpo, fragmento de ligação de antìgeno, composição farmacêutica, métodos de tratar um paciente humano afligido com uma doença ou distúrbio, de triar um anticorpo, e de detectar hosm em uma amostra biológica, uso de um anticorpo terapêutico ou fragmento de ligação de antìgeno, medicamento, vetor, polunucleotìdeo, célula hospedeira recombinante estavelmente transformada ou transfectada, e, processo para a fabricação de um anticorpo terapêutico | |
| JP2007526770A5 (pt) | ||
| Farkas et al. | Heparin-binding epidermal growth factor-like growth factor (HB-EGF) regulates survival of midbrain dopaminergic neurons | |
| Meiners et al. | Identification of a neurite outgrowth-promoting motif within the alternatively spliced region of human tenascin-C | |
| BRPI0509278A (pt) | polipeptìdeo isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira isolada, linhagem de célula empacotadora, dispositivo celular biocompatìvel implantável, composição farmacêutica, uso do polipeptìdeo, ou da seqüência de ácido nucléico isolada, ou do vetor de expressão, ou de uma composição de células hospedeiras, ou de um dispositivo celular biocompatìvel implantável ou de uma linhagem de célula empacotadora, método de tratamento de uma condição patológica em um indivìduo, métodos para prevenir a apoptose em uma célula neuronal de mamìfero, para realçar a sobrevivência de uma célula neuronal de mamìfero, para gerar um neurÈnio, para expandir uma composição de células de mamìfero, e para diferenciar uma composição de células de mamìfero, anticorpo, e, imunoconjugado | |
| Rask | Biological actions of nerve growth factor in the peripheral nervous system | |
| Joshi et al. | Loss of Schwann cell plasticity in chronic inflammatory demyelinating polyneuropathy (CIDP) | |
| Inoue et al. | Spontaneous regeneration of the pyramidal tract after transection in young rats | |
| Severi et al. | Constitutive expression of ciliary neurotrophic factor in mouse hypothalamus | |
| Siebert et al. | Select neurotrophins promote oligodendrocyte progenitor cell process outgrowth in the presence of chondroitin sulfate proteoglycans | |
| Puentes et al. | Brain microvascular endothelial cell transplantation ameliorates ischemic white matter damage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014. |